Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company, announced its upcoming participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference. The company, which specializes in developing customizable, incision-free therapies for diseased tissue ablation, will present a business update on Tuesday, May 6, 2025, at 1:30 p.m. Eastern Time.
The presentation will take place at the Metro Toronto Convention Centre. Investors and interested parties can access the live broadcast and archived recording through the "Webcasts" section under Investors on the company's website at www.profoundmedical.com.
Profound Medical (NASDAQ:PROF; TSX:PRN), un'azienda di dispositivi medici in fase commerciale, ha annunciato la sua prossima partecipazione alla Conferenza per Investitori nel Settore Sanitario 2025 di Bloom Burton & Co.. L'azienda, specializzata nello sviluppo di terapie personalizzabili e senza incisioni per l'ablazione di tessuti malati, presenterà un aggiornamento aziendale martedì 6 maggio 2025 alle 13:30 ora orientale.
La presentazione si svolgerà presso il Metro Toronto Convention Centre. Investitori e persone interessate potranno seguire la diretta streaming e accedere alla registrazione archiviata nella sezione "Webcasts" all'interno della pagina Investitori sul sito web dell'azienda www.profoundmedical.com.
Profound Medical (NASDAQ:PROF; TSX:PRN), una empresa de dispositivos médicos en etapa comercial, anunció su próxima participación en la Conferencia de Inversores en Salud 2025 de Bloom Burton & Co.. La compañía, especializada en el desarrollo de terapias personalizables y sin incisiones para la ablación de tejidos enfermos, presentará una actualización comercial el martes 6 de mayo de 2025 a la 1:30 p.m., hora del Este.
La presentación tendrá lugar en el Metro Toronto Convention Centre. Los inversores y las partes interesadas podrán acceder a la transmisión en vivo y a la grabación archivada a través de la sección "Webcasts" en la página de Inversores del sitio web de la compañía www.profoundmedical.com.
Profound Medical(NASDAQ:PROF; TSX:PRN)는 상업 단계의 의료기기 회사로서 2025년 Bloom Burton & Co. 헬스케어 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 맞춤형 무절개 질환 조직 절제 치료법 개발을 전문으로 하는 이 회사는 2025년 5월 6일 화요일 동부 표준시 기준 오후 1시 30분에 사업 업데이트를 발표할 예정입니다.
발표는 메트로 토론토 컨벤션 센터에서 진행됩니다. 투자자 및 관심 있는 분들은 회사 웹사이트 www.profoundmedical.com의 투자자 섹션 내 "Webcasts"를 통해 생중계 및 녹화 영상을 시청할 수 있습니다.
Profound Medical (NASDAQ:PROF; TSX:PRN), une entreprise de dispositifs médicaux en phase commerciale, a annoncé sa prochaine participation à la Conférence des investisseurs en santé 2025 de Bloom Burton & Co.. L'entreprise, spécialisée dans le développement de thérapies personnalisables sans incision pour l'ablation des tissus malades, présentera une mise à jour commerciale le mardi 6 mai 2025 à 13h30, heure de l'Est.
La présentation aura lieu au Metro Toronto Convention Centre. Les investisseurs et parties intéressées pourront accéder à la diffusion en direct et à l'enregistrement archivé via la section "Webcasts" sous Investisseurs sur le site web de l'entreprise www.profoundmedical.com.
Profound Medical (NASDAQ:PROF; TSX:PRN), ein medizinisches Geräteunternehmen in der kommerziellen Phase, gab seine bevorstehende Teilnahme an der Bloom Burton & Co. Healthcare Investor Conference 2025 bekannt. Das Unternehmen, das sich auf die Entwicklung anpassbarer, schnittfreier Therapien zur Ablation erkrankten Gewebes spezialisiert hat, wird am Dienstag, den 6. Mai 2025, um 13:30 Uhr Eastern Time ein Unternehmensupdate präsentieren.
Die Präsentation findet im Metro Toronto Convention Centre statt. Investoren und Interessierte können die Live-Übertragung und die archivierte Aufnahme über den Bereich "Webcasts" unter Investoren auf der Unternehmenswebsite www.profoundmedical.com abrufen.
- Presentation at a major healthcare investor conference indicates active investor relations and potential visibility to institutional investors
- Company maintains commercial-stage status with marketed medical device products
- None.
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre.
The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When is Profound Medical (PROF) presenting at the 2025 Bloom Burton Healthcare Conference?
How can I watch Profound Medical's (PROF) 2025 Bloom Burton Conference presentation?
What type of medical technology does Profound Medical (PROF) develop?
Where is Profound Medical's (PROF) 2025 Bloom Burton Conference presentation taking place?
Which stock exchanges is Profound Medical (PROF) listed on?
